Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial

Annual influenza vaccination greatly reduces morbidity and mortality, but effectiveness remains sub-optimal. Weaknesses of current vaccines include low effectiveness against mismatched strains, lack of mucosal and other effective tissue-resident immune responses, weak cellular immune responses, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tasker, Sybil, Wight O’Rourke, Anna, Suyundikov, Anvar, Jackson Booth, Peta-Gay, Bart, Stephan, Krishnan, Vyjayanthi, Zhang, Jianfeng, Anderson, Katie J., Georges, Bertrand, Roberts, M. Scot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000446/
https://www.ncbi.nlm.nih.gov/pubmed/33807649
http://dx.doi.org/10.3390/vaccines9030224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000446/
https://www.ncbi.nlm.nih.gov/pubmed/33807649
http://dx.doi.org/10.3390/vaccines9030224

Ejemplares similares